Researchers at the University of Edinburgh, led by Professor Peter Sadler, have developed a novel series of platinum prodrugs, which can be activated by light (photoactivated).

Researchers at the University of Edinburgh, led by Professor Peter Sadler, have developed a novel series of platinum prodrugs, which can be activated by light (photoactivated). In partnership with Dr Julie Woods, at the University of Dundee, these prodrugs have been shown to exhibit cytotoxic activity in vitro. We believe this offers a novel approach to platinum chemotherapy to significantly reduce associated side effects and introduce a new mechanism of action. This novel approach uses photochemical changes in platinum prodrugs (Pt IV) to deliver novel cytotoxic species to the tumour site. This offers a very distinctive advantage over conventional Photodynamic therapy (PDT) in that the anti- cancer activity is not dependent on oxygen which is often limited at the tumour site. Preliminary biological testing, at the University of Dundee's Photobiology Unit, has demonstrated potent in vitro phototoxicity with selected lead compounds. The majority of compounds were equal in potency to or better than cisplatin in the light, especially in ovarian carcinoma cells, under the conditions used. Key Benefits: * Cytotoxic activity is regulated by PhotoActivation which should enable tumour specific treatment; * Pt IV prodrugs are relatively non-toxic in vitro until activation; * PhotoActivated Pt species do not require oxygen for anti- cancer activity; * The mechanism of action is different from existing platinum cytotoxic agents. Applications: These platinum-based prodrugs are ideally suited to the treatment of solid tumours where photoactivation is applicable. Based on conventional platinum-cytotoxic agents, such as cisplatin, these compounds are likely to be useful against a range of solid tumours, including: adrenal cortex; breast; lung; ovarian; and testicular.

Early Stage

The compounds are subject to patent application (Ref No. WO03/017993) which is available for licensing. This project was supported by the Scottish Enterprise Proof of Concept Fund.

The University of Edinburgh is seeking partners to develop this product series for human and animal healthcare in particular as anti-cancer agents. The preferred structure would be a collaborative partnership which would combine the knowledge of Professor Sadler and Dr Woods with the drug development capability of an industrial partner.